TP 10 - Tillotts Pharma

Drug Profile

TP 10 - Tillotts Pharma

Alternative Names: TP-10 - Tillotts Pharma

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tillotts Pharma
  • Class Anti-inflammatories; Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 22 Mar 2018 Tillotts Pharma licenses Cell Line Technology from BioWa and Lonza for the development of TP 10
  • 22 Jan 2018 Tillotts Pharma in-licenses certain rights for the antibody technology developed at the University of Oslo and Oslo University Hospital
  • 22 Jan 2018 Preclinical trials in Inflammatory bowel disease in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top